ARTICLE | Financial News
Esperion planning $85M follow-on
October 15, 2014 1:45 AM UTC
Esperion Therapeutics Inc. (NASDAQ:ESPR) proposed to raise up to $85 million in a follow-on underwritten by J.P. Morgan and BofA Merrill Lynch.
The offering will help fund Phase III testing of ETC-1002, which is an AMP-activated protein kinase ( AMPK) activator and ATP citrate lyase (ACL) inhibitor in Phase II testing to treat hypercholesterolemia. The company plans to begin Phase III testing by YE15, with regulatory submissions expected in mid-2018. ...